SELLAS Life Sciences shares plunge 19%: What triggered the sharp sell-off?
SELLAS Life Sciences shares plunged nearly 20% after the biotechnology company priced a $150 million public offering at $13 per share, a discount of around 28% to its previous close. The sell-off followed a sharp rally triggered by positive Phase 3 REGAL trial results for its experimental leukemia vaccine.
Shares of SELLAS Life Sciences Group (NASDAQ: SLS) plunged nearly 20% in overnight trading after the biotechnology company announced a discounted $150 million share offering. The sell-off came just a day after the stock rallied sharply on positive topline results from its late-stage leukemia vaccine trial. (Sources: TradingView, Yahoo Finance)
SELLAS priced its public offering of 11.54 million new shares at $13 apiece, raising approximately $150 million in gross proceeds. The offer price represented a discount of around 28% to the stock's previous closing price of $17.95, triggering concerns over dilution among existing shareholders.
The company also granted underwriters a 30-day option to purchase up to 1.73 million additional shares at the offering price. If fully exercised, the transaction could generate gross proceeds of approximately $172.5 million. The offering was expected to close on November 20, subject to customary conditions.
The latest decline followed a massive rally after SELLAS announced positive topline results from its Phase 3 REGAL trial for its experimental cancer vaccine, galinpepimut-S (GPS). The trial demonstrated a 41% reduction in the risk of death, with median overall survival of 24 months compared with 14.7 months for patients receiving the best available treatment. The results helped send the stock up more than 150% earlier in the week.
Despite the share-price volatility, SELLAS is preparing to meet with the US Food and Drug Administration to discuss its vaccine development programme. The company aims to submit a Biologics License Application for galinpepimut-S in the first half of 2027. Proceeds from the latest offering are expected to support clinical development, preparations for a potential commercial launch and general corporate requirements.